ABSTRACT
Weight loss and long-term weight maintenance of 5% to 10% of initial weight are considered adequate to improve cardiovascular risk factors and other obesity-related conditions. Lifestyle modification remains the most important tool in obesity management through the combination of dietary modification, an increase in physical activity, formal exercise regimens, and behavioral and cognitive therapy. As adjunctive treatment, antiobesity medications have been approved and recommended for
1. Patients who have a BMI27 kg/m2 in the presence of two or more than two obesity-related medical conditions including established coronary heart disease, type 2 diabetes mellitus, hypertension, dyslipidemia, cerebrovascular disease, severe osteoarthritis, and sleep apnea and
2. Patients with a BMI30 kg/m2.
